Latest news about Gufic BioSciences
Gufic BioSciences
353.20
-10.85(-2.98%)
Company Performance:
View Company Insights1D-2.98%
1M+16.78%
6M+2.90%
1Y-5.49%
5Y+93.38%
More news about Gufic BioSciences
22May 26
Gufic Biosciences board to meet on May 29 for FY26 results
Gufic Biosciences Limited will hold a board meeting on May 29, 2026, to approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board will also evaluate a final dividend proposal for FY26. The trading window for insiders stays closed until 48 hours after the results are announced.
30Apr 26
Gufic Biosciences Completes USD 50,000 Investment in Selvax Pty Ltd Under Regulation 30
Gufic Biosciences has completed a strategic USD 50,000 investment in Selvax Pty Ltd, an Australian biotechnology company developing novel immunology-based cancer treatments. The transaction involved acquiring 378,350 ordinary shares at AUD 0.20 per share, bringing the total shareholding to 16,85,350 shares. This investment aligns with the company's diversification strategy into healthcare and biotechnology sectors.
15Apr 26
Gufic Biosciences Opens Special Window for Physical Share Transfer and Dematerialization
Gufic Biosciences Limited has opened a special window from February 05, 2026 to February 04, 2027 for re-lodgement of transfer deeds and dematerialization of physical shares, following SEBI Circular dated January 30, 2026. The facility covers securities sold or purchased before April 01, 2019, including previously rejected transfers. Transferred securities will be credited in demat mode with a one-year lock-in period.
07Apr 26
Gufic Biosciences Submits Q4 FY26 Compliance Certificate Under SEBI Depositories Regulations
Gufic Biosciences Limited filed its Q4 FY26 compliance certificate under SEBI Depositories Regulations on April 07, 2026. The certificate, submitted to BSE and NSE by Company Secretary Ami Shah, covers the quarter ended March 31, 2026. Registrar MUFG Intime India confirmed no dematerialisation requests were received during the period, with the filing made purely for regulatory compliance purposes.
03Apr 26
Gufic Biosciences Receives Rs 23.52 Lakh Penalty Demand for Under-Reported Income in FY24
Gufic Biosciences Limited has received a penalty demand of Rs 23,52,396 from the Income Tax Department under Section 270A(9) for Assessment Year 2023-24 related to under-reported income. The company previously succeeded in reducing a tax demand from Rs 11,88,88,580 to Rs 11,76,198 through appeal. Gufic Biosciences plans to file an appeal against the penalty order and remains confident of a favorable outcome based on tax consultant advice.
13Mar 26
Gufic Biosciences Pays ₹1.72 Lakh Penalty to BSE After Waiver Application Rejection
Gufic Biosciences Limited paid ₹1.72 lakh penalty to BSE on March 13, 2026, after its waiver application was rejected. The penalty was imposed for non-compliance with SEBI regulations regarding the appointment of Mr. Kamal Kishore Seth as independent director above 75 years without shareholders' approval. The company had earlier paid ₹8,000 each to BSE and NSE for the June 2024 quarter related to the same violation.
13Feb 26
Gufic Biosciences Releases Q3FY26 Investor Presentation with Financial Results
Gufic Biosciences reported Q3FY26 revenue of ₹231.10 crore, up 11.22% year-on-year, though profit margins declined with PAT falling to ₹15.60 crore. The company's Indore facility achieved 30% capacity utilization with production capabilities across multiple injectable formats, while maintaining strong regulatory compliance across its diversified pharmaceutical platform.
20Jan 26
Gufic Biosciences Receives Income Tax Demand of ₹4.33 Crores for Assessment Year 2024-25
Gufic Biosciences Limited received a ₹4.33 crores income tax demand for Assessment Year 2024-25 due to expenditure disallowance under Section 143(1)(a). The company received the December 22, 2025 order on January 19, 2026, and plans to file an appeal with the Commissioner of Income Tax (Appeal). Management remains confident of a favorable outcome based on legal advice and case merits.
27Dec 25
Gufic Biosciences Receives GST Penalty Order of ₹15.64 Lakh for FY2018-19 to FY2022-23
Gufic BioSciences has been issued a GST penalty order of ₹15,64,052 by tax authorities for the period FY2018-19 to FY2022-23. The penalty includes ₹15,35,080 for excess Input Tax Credit claims and ₹28,972 for short payment of tax liability. The company plans to contest the penalties by filing an appeal and believes there will be no material impact on its financial operations or business activities.
13Aug 25
Gufic Biosciences Reports Q1 Results: Revenue Up, Profit Down Amid Rising Costs
Gufic BioSciences, an Indian pharmaceutical company, released its Q1 financial results. Consolidated revenue increased by 10.3% to ₹223.72 crore, up from ₹202.81 crore in the previous year. However, net profit declined by 37.3% to ₹13.07 crore from ₹20.86 crore. EBITDA decreased by 9.8% to ₹32.30 crore, with the EBITDA margin falling by 339 basis points to 14.25%. The company faced increased material costs, higher employee benefits expenses, and doubled finance costs. Gufic BioSciences continues to operate solely in the pharmaceuticals segment.
30May 25
Gufic Biosciences Reports Mixed Q4 Results: Revenue Up, Profits Down
Gufic Biosciences' Q4 financial results show a 5.13% increase in revenue to ₹2.05 billion, but a significant decline in profitability. EBITDA fell to ₹266.00 million from ₹342.30 million year-over-year, with EBITDA margin dropping to 12.99% from 17.55%. Net profit sharply decreased to ₹80.00 million from ₹200.00 million in the previous year. The company faces challenges in maintaining profit margins despite revenue growth.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,794.20
(+0.44%)
6,655.50
(+0.26%)
4,572.20
(+2.43%)
1,383.30
(+0.46%)
1,105.90
(+0.69%)
1,276.00
(+0.34%)
2,273.30
(+1.16%)
2,372.70
(-0.15%)
1,464.10
(+0.72%)
1,390.80
(+0.37%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
